South India's most experienced reproductive genetics laboratory — a decade of expertise, 5000+ embryos tested, and a full spectrum of cytogenetic and molecular genetic services.
PGT-A via Ion Torrent NGS — whole-chromosome copy number analysis for all 24 chromosomes, every embryo
Led by Dr. Jayaram and Dr. Swathi — specialist geneticists with deep expertise in reproductive and clinical genetics
PGT-A · PGT-M · PGT-SR · NIPT · Karyotyping · FISH · HLA Typing — all under one roof in Bangalore
Rapid reporting designed around your IVF cycle windows — fresh and frozen transfer timelines respected
Genetic testing sounds complex — we make it simple, compassionate, and clear. Whether you are beginning IVF or have had recurrent losses, our team will guide you every step of the way.
We are your dedicated genetics partner — rigorous NGS methodology, deep clinical integration, and a scientific team that speaks your language.
A full suite of cytogenetic and molecular genetic tests — preimplantation, prenatal, and postnatal.
NGS-based screening of all 24 chromosomes in IVF embryos to identify euploid embryos for transfer.
For couples carrying known single-gene mutations — Beta-Thalassemia, DMD, OI, Glycogen Storage Disorders, and more.
For couples with balanced chromosomal translocations or inversions to prevent miscarriage and affected offspring.
A simple blood draw detecting Trisomy 21, 18, 13 and sex chromosome aneuploidies with >99% accuracy.
Standard chromosome analysis and targeted fluorescence probes for infertility workup and prenatal diagnosis.
Human Leucocyte Antigen typing for recurrent implantation failure, RPL, and saviour sibling programmes.
"Our mission: reliable genetic testing using the most advanced technology, to help every couple achieve a healthy pregnancy."
Founded in 2015, Tattvagene was built with a singular focus — to bring the precision of cutting-edge reproductive genetics directly into the IVF workflow. Over the past decade, we have grown into one of India's most experienced reproductive genetics centres, having performed over 5000 PGT-A analyses.
Our laboratory is equipped with Next Generation Sequencing (NGS) on the Thermo Fisher Ion Torrent platform, delivering whole-chromosome copy number analysis across all 24 chromosomes with high sensitivity for mosaicism detection.
From standard PGT-A through complex monogenic disorder testing for conditions like Beta-Thalassemia, Duchenne Muscular Dystrophy, and Osteogenesis Imperfecta, we offer a comprehensive genetic testing suite. We welcome referrals from all IVF centres and fertility specialists across India.
#365, Sulochana Building, 1st Cross Road, 3rd Block, Sarjapur Main Road, Koramangala, Bengaluru — 560 034
Thermo Fisher Ion Torrent semiconductor NGS — rapid, accurate, whole-chromosome copy number profiling
One of India's longest-running dedicated reproductive genetics laboratories — over 5000 PGT-A cases performed with consistent quality.
Semiconductor sequencing delivers high-resolution chromosomal analysis including mosaicism detection that microarrays cannot match.
Our TAT is designed to fit your freeze-all and frozen transfer protocols without delays — because every day matters in an IVF cycle.
We welcome referrals from all IVF clinics and fertility specialists regardless of affiliation. Every patient deserves access to excellent genetics.
Our scientific directors are available for pre-test consultation and post-report discussion on complex PGT-M and mosaic embryo cases.
PGT-A, PGT-M, PGT-SR, NIPT, Karyotyping, FISH, HLA Typing — one laboratory for your full reproductive genetics needs.
From embryo screening to prenatal diagnosis — a complete suite of cytogenetic and molecular genetic tests, all under one roof.
NGS-based screening of all 24 chromosomes in IVF embryos to identify euploid embryos for transfer. Reduces implantation failure and miscarriage rates, and improves live birth rates — particularly in advanced maternal age, recurrent implantation failure, and recurrent pregnancy loss. We use the Ion Torrent platform for quantitative copy number analysis including mosaicism detection and reporting per current PGDIS/ESHRE guidelines.
For couples carrying known single-gene mutations. We test embryos for the specific familial variant so only unaffected embryos are transferred. Conditions we have managed include Beta-Thalassemia, Duchenne Muscular Dystrophy, Osteogenesis Imperfecta, and Glycogen Storage Disorders. Saviour sibling programmes combining PGT-M with HLA matching are available. Pre-test workup (4–8 weeks) is required for each new condition.
For couples with balanced chromosomal translocations (reciprocal and Robertsonian) or inversions. These couples risk generating embryos with unbalanced chromosomal material, leading to miscarriage or chromosomally affected offspring. PGT-SR uses NGS-based copy number analysis to identify chromosomally balanced embryos suitable for transfer, significantly improving live birth outcomes.
A simple maternal blood draw from 10 weeks gestation. Cell-free fetal DNA analysis screens for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), Trisomy 13 (Patau syndrome), and sex chromosome aneuploidies with a detection rate exceeding 99%. Safe, accurate, and carries no risk to the pregnancy. Suitable for singleton and twin pregnancies including IVF conceptions.
Standard G-banding karyotype analysis for couples with infertility, recurrent miscarriage, or a family history of chromosomal disorders. Detects numerical and structural chromosome abnormalities. Essential pre-ART workup for both partners. Available for prenatal samples (amniocyte/CVS) and postnatal blood samples. Results inform assisted conception planning and genetic counselling.
Targeted detection of chromosomal abnormalities using fluorescent DNA probes. Applications include microdeletion syndromes (Prader-Willi/Angelman), sex chromosome verification (SRY), sperm FISH for males with severe oligospermia or azoospermia, and rapid aneuploidy screening in prenatal samples. Complements karyotyping where higher resolution is needed for specific loci.
HLA typing for recurrent implantation failure (RIF) and recurrent pregnancy loss (RPL) investigation. Couples with excessive HLA allele sharing may have impaired immunological tolerance of the conceptus. Also used in PGT-M + HLA programmes for saviour sibling selection (e.g. for stem cell donation to an affected sibling), and in haematopoietic stem cell transplant workup.
We run PGT-A and NGS-based tests on the Thermo Fisher Ion Torrent semiconductor sequencing platform — delivering speed, accuracy, and scalability that conventional microarrays cannot match.
Direct detection of nucleotide incorporation with no optical imaging required. Delivers rapid, cost-effective whole-genome copy number profiling at clinical-grade quality for reproductive genetics applications.
Simultaneous screening of all 24 chromosomes (22 autosomes + X + Y) in a single run. Identifies full aneuploidies and segmental imbalances across the entire genome — no targeted probes, no coverage gaps.
Quantitative NGS read-depth analysis enables classification and reporting of mosaic embryos with percentage estimates, following current PGDIS/ESHRE guidelines for clinical decision-making support.
Workflow optimised for Day 5/6 trophectoderm biopsy at the blastocyst stage. Also compatible with Day 3 cleavage-stage biopsy and single-cell samples where clinically required.
Targeted sequencing of disease-causing variants combined with haplotype-based linkage analysis — enabling PGT-M for virtually any single-gene disorder with a known familial variant.
Maternal plasma cfDNA isolation and massively parallel sequencing for non-invasive prenatal detection of common trisomies and sex chromosome aneuploidies with >99% sensitivity and specificity.
We know that fertility treatment is emotionally and medically overwhelming. This guide explains everything you need to know about genetic testing during your IVF journey — in plain, compassionate language.
The single biggest reason IVF cycles fail or result in miscarriage is that the embryo has an abnormal number of chromosomes — a condition called aneuploidy. In fact, more than 50% of all human embryos are chromosomally abnormal, and this proportion increases significantly with the mother's age.
Genetic testing allows us to examine the chromosomes inside your embryos before transfer, so your doctor can select only healthy, chromosomally normal (euploid) embryos. This dramatically improves your chances of a successful pregnancy and healthy baby.
At Tattvagene, we use Next Generation Sequencing (NGS) on the Thermo Fisher Ion Torrent platform — the most advanced and accurate technology available for embryo testing — to analyse all 24 chromosomes simultaneously.
Over 50% of early miscarriages are caused by chromosomal abnormalities in the embryo — not by anything the mother did or didn't do.
At age 35, around 40% of embryos are chromosomally abnormal. By age 40, this rises to over 70%. PGT-A helps identify the healthy ones.
Trophectoderm biopsy removes just 5–10 cells from the part of the embryo that becomes the placenta — not the baby. Thousands of healthy babies have been born after this procedure worldwide.
Here is exactly what happens from the moment your doctor recommends genetic testing to the day of your embryo transfer.
Your IVF specialist will discuss whether genetic testing is appropriate for your specific situation. This is usually recommended if you are 35 or older, have had previous failed IVF cycles, have experienced recurrent miscarriage, have a known genetic condition in the family, or have a partner with a chromosomal abnormality. There is no obligation — your doctor will help you make an informed decision.
You undergo your normal IVF stimulation cycle — hormone injections to grow multiple eggs, followed by egg collection under sedation. The eggs are fertilised in the laboratory, and the resulting embryos are grown to Day 5 or Day 6 (the blastocyst stage). This part of the process is identical to a standard IVF cycle.
On Day 5 or 6, your embryologist carefully removes 5–10 cells from the outer layer (trophectoderm) of each blastocyst embryo. This layer becomes the placenta — not the baby — so this procedure does not harm the embryo. You will not feel anything as this happens in the laboratory. Each embryo is given a unique ID so results can be matched exactly. After biopsy, your embryos are vitrified (frozen) at ultra-low temperature and safely stored until your transfer cycle.
The biopsy samples are carefully transported to our laboratory in Koramangala, Bengaluru. Our scientists analyse the DNA from each sample using the Ion Torrent NGS platform, examining all 24 chromosomes (chromosomes 1–22, X and Y) in a single test. We look for extra or missing chromosomes (aneuploidy), as well as mosaic findings (where some cells are normal and some are not). Results are typically ready within a few working days.
Your doctor receives a detailed report for each embryo, classifying it as euploid (chromosomally normal — highest chance of a healthy pregnancy), aneuploid (chromosomally abnormal — not suitable for transfer), or mosaic (a mixture of normal and abnormal cells — your doctor will discuss the implications). Your doctor will explain the results and help you decide which embryo to transfer first.
In the following cycle, your uterine lining is prepared with hormones, and your best euploid embryo is thawed and transferred. This is a simple, painless procedure similar to a smear test. Because the embryo has been selected based on its chromosomal status, your chance of successful implantation is significantly higher than in an untested cycle. If you have multiple euploid embryos, the remaining ones stay frozen safely for future attempts.
Tattvagene offers several different genetic tests. Your doctor will advise which is most appropriate, but here is a plain-language guide to each.
No test can guarantee a pregnancy. However, PGT-A significantly improves your chances per transfer by ensuring only chromosomally normal embryos are transferred. It reduces wasted cycles on embryos that would not have implanted or would have miscarried.
This is hard news to receive. However, knowing this early means you can pursue another stimulation cycle rather than going through failed transfers. Your fertility doctor will discuss all options including a further cycle, donor eggs, or adoption.
A mosaic embryo has a mixture of chromosomally normal and abnormal cells. Some mosaic embryos have been transferred successfully and resulted in healthy babies. The decision to transfer a mosaic embryo is a clinical one — your doctor and our team will explain what the specific findings mean for your embryo and help you decide.
The biopsy is performed on the embryo in the laboratory — you will not be present and will feel nothing. It is a very precise procedure performed by skilled embryologists under a microscope and does not involve any procedure on you.
After your embryo biopsy, results are typically available within a few working days. Your embryo transfer then happens in the following cycle — usually 4–6 weeks after biopsy. For PGT-M, an additional 4–8 week pre-test workup is needed before your IVF cycle begins.
Yes — NIPT is a prenatal test done from 10 weeks of an existing pregnancy. It screens for chromosomal conditions using a simple blood draw and carries no risk to the baby. If you are pregnant and concerned, please contact us or speak to your obstetrician.
Our team is here to answer every question, no matter how big or small. Reach out today and we will help you understand your options.
We work alongside IVF clinics and fertility specialists across India — providing rigorous NGS-based genetic testing, streamlined referral coordination, and expert clinical support for every case.
We run PGT-A on the Thermo Fisher Ion Torrent semiconductor sequencing platform — delivering whole-genome copy number analysis across all 24 chromosomes with quantitative mosaicism detection. NGS outperforms arrays in resolution, sensitivity, and clinical utility.
Each PGT-A report includes chromosomal status for all 24 chromosomes per embryo, quantified mosaic calls with percentage estimates, segmental imbalance reporting, and clinical guidance notes. Reporting follows current PGDIS/ESHRE international guidelines.
Our TAT is designed specifically around freeze-all protocols and frozen embryo transfer cycles. Results are delivered within a few working days of sample receipt. For time-sensitive cases, expedited reporting is available — contact us to discuss.
We accept referrals from all IVF clinics and fertility specialists regardless of affiliation, size, or location. Our services are available to the entire fertility community across Karnataka and beyond.
Our scientific directors — Dr. Jayarama S. Kadandale and Dr. Swathi Shetty — are available for pre-test consultation on complex cases, post-report clinical discussion, and support for mosaic embryo transfer decisions. We speak your clinical language.
Founded in 2015, Tattvagene is one of India's most experienced reproductive genetics laboratories. With over 5000 PGT-A cases performed, our clinical knowledge and quality assurance systems are proven at scale.
Thermo Fisher Ion Torrent semiconductor NGS. Whole-genome copy number analysis across all 24 chromosomes (22 autosomes + X + Y) per embryo per run. Quantitative read-depth method enables both full aneuploidy calling and mosaic detection with percentage estimation.
Family-specific assay design using haplotype-based linkage analysis combined with direct mutation detection. A pre-test workup of 4–8 weeks is required per new condition before the IVF cycle. Proband and/or carrier samples are needed for assay design.
Saviour sibling programmes (PGT-M + HLA matching) available for couples seeking a histocompatible donor sibling for an affected child. Contact our scientific directors to discuss feasibility for complex or rare conditions.
NGS-based whole-genome copy number profiling identifies unbalanced chromosomal rearrangements in embryos from carriers of reciprocal translocations, Robertsonian translocations, and chromosomal inversions. Results identify embryos with a balanced or normal chromosomal complement suitable for transfer.
cfDNA-based screening from 10 weeks gestation. >99% detection rate for Trisomies 21, 18, 13 and sex chromosome aneuploidies. Suitable for singleton and twin pregnancies including IVF conceptions. Maternal plasma collected in Streck tubes; 10 mL required.
Report time: typically within 5 working days of sample receipt.
G-banded karyotyping from peripheral blood (lithium heparin) or prenatal samples (amniocentesis/CVS). FISH panels for microdeletion syndromes, SRY verification, and sperm FISH. HLA typing for RIF/RPL workup and PGT-M + HLA (saviour sibling) programmes.
Contact us for specific sample requirements and turnaround times.
We have designed our referral and coordination process to be as frictionless as possible for busy fertility clinics. Here is how it works, step by step.
Call or email us with the patient's clinical background — indication for testing, number of embryos expected, any known genetic conditions in the family, and the test required. Our scientific directors are available to discuss complex or unusual cases before you formally refer. For PGT-M, this initial consultation is essential to assess feasibility and plan the pre-test workup timeline.
We provide test-specific request forms, patient consent forms (in English and Kannada), and sample collection guidelines. For PGT-A, biopsy collection protocol and transport guidelines are provided to your embryology lab. For PGT-M, additional family history forms and requirements for proband/carrier blood samples will be issued.
For PGT-A and PGT-SR: trophectoderm biopsy is performed by your embryologist on Day 5 or 6 blastocysts. Biopsy cells are collected in labelled 0.2 mL PCR tubes with minimal PBS. Embryos are vitrified immediately post-biopsy. Samples are transported to our laboratory fresh on dry ice or as pre-vitrified biopsy cells — we coordinate logistics with your embryology team to ensure optimal handling and chain-of-custody documentation.
On receipt, samples undergo whole genome amplification (WGA) followed by NGS library preparation and sequencing on our Ion Torrent platform. Internal QC metrics (amplification efficiency, sequencing coverage, noise levels) are checked at each stage. Samples that fail QC are flagged immediately and re-analysis options discussed with you before final reporting.
Reports are delivered securely to the referring clinician via email in PDF format. Each PGT-A report includes: a summary table of all embryos with chromosomal classification, detailed chromosome plots per embryo, mosaic findings with % estimates per affected chromosome, a clinical notes section, and the reporting scientist's signature. Reports follow the PGDIS/ESHRE international classification criteria.
Our scientific directors are available for clinician-to-clinician discussion on complex findings — particularly mosaic embryo transfer decisions, segmental imbalance interpretation, and PGT-M result counselling. We can also provide written case summaries for complex cases on request. Patient-facing genetic counselling support can be arranged through our team where needed.
Contact us to receive our complete sample collection and transport guidelines document, including request forms, consent templates, and chain-of-custody forms tailored for your laboratory.
Our team is ready to assist — from initial case discussion through to report interpretation. Get in touch today.
Our laboratory is led by specialist geneticists and supported by a dedicated team of clinical laboratory scientists with deep expertise across cytogenetics and molecular genetics.
PhD from University of Mysore; trained at Indian Institute of Science, Bangalore; University of Tennessee Health Science Centre, Memphis; and Memorial Sloan Kettering Cancer Centre, NY. Licensed Specialist in Clinical & Molecular Cytogenetics (Tennessee, USA). Over 25 years of experience in clinical and molecular cytogenetic investigations for prenatal, neonatal, microdeletion, fertility, and cancer diagnostics.
PhD in Genetics from La Trobe University, Australia. Over 18 years of experience in molecular genetic research and diagnostics. Instrumental in establishing Molecular Diagnostics (DNA diagnostics), Prenatal Genetic Diagnostics, and NGS-based testing in both research and clinical diagnostic settings.
BE in Biotechnology from PA College of Engineering, Mangalore (VTU). Worked at Centre for Human Genetics, Bangalore (2014–2015). Joined Tattvagene in 2015 as Clinical Laboratory Scientist – Molecular. Extensive expertise in NGS technology, HLA sequence analysis, and prenatal and postnatal techniques.
BE in Biotechnology from New Horizon College of Engineering, Bangalore (VTU) and MBA in International Business from Annamalai University. Worked at Centre for Human Genetics (2013–2015). Joined Tattvagene in 2015 as Clinical Laboratory Scientist – Cytogenetics.
M.Sc. in Genetics from University of Mysore. Research Assistant at Centre for Human Genetics, Bangalore (2019–2021). Currently working as Scientific Assistant in the molecular department at Tattvagene.
Master's in Applied Genetics. Currently working as Scientific Assistant Trainee in the cytogenetics department at Tattvagene. Previously worked as a freelance academic editor.
Whether you have a complex clinical case or would like to discuss the right test for your patient, our scientific directors are available for consultation.
Contact Us →Whether you are a patient seeking information about genetic testing or a fertility specialist looking to refer a patient, we are here to help. We will respond promptly.
#365, Sulochana Building, 1st Cross Road, 3rd Block
Sarjapur Main Road, Koramangala, Bengaluru — 560 034
Monday – Saturday: 9:00 AM – 6:00 PM
Sunday: By appointment